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with temozolomide against primary glioblastomas and demon-
strated that this treatment protocol prolonged the overall survival 
(OS) and progression-free survival (PFS) of patients when com-
pared with the previous standard treatment. Since that report, 
CCRT and adjuvant chemotherapy with temozolomide have 
been recognized as the primary treatment for newly diagnosed 
glioblastoma, and temozolomide as an essential chemotherapeu-
tic drug for primary glioblastoma treatment13).
Therefore, we designed a prospective multicenter trial to con-
firm that if Stupp’s treatment protocol was also effective and 
safe in Korean patients with newly diagnosed glioblastomas. 
The aims of this study were to settle on a standard treatment 
INTRODUCTION
Glioblastoma, a frequent primary intracranial malignant tu-
mor, presents with a dismal prognosis despite multimodal treat-
ment modalities, such as surgery, radiotherapy and chemothera-
py4). Most patients who are diagnosed with primary glioblastoma 
die within two years even in the most favorable situations. Re-
cently, a number of studies and trials have been performed to de-
velop new drugs and interventions against this terrible disease.
In 2005, Stupp et al.17,18) reported the results of the first prospec-
tive multi-institutional randomized controlled trial of concurrent 
chemoradiotherapy (CCRT) followed by adjuvant chemotherapy 
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Conclusion : This study is the first prospective multi-institutional report of CCRT and adjuvant chemotherapy with temozolomide for patients with a 
newly diagnosed glioblastoma in Korea. The current protocol may prolong the survival of Korean patients with a glioblastoma and may be tolerable 
in terms of toxicity.
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ing immediate postoperative MR images within 72 hours after 
surgery. The gross total removal (GTR) was defined as >99% 
removal of the initial tumor, the subtotal removal (STR) as 50-
99%, and the partial removal (PR) as <50%. Tumor progression 
was defined as a 25% increase in the maximal tumor area, the 
appearance of new lesions, and an increased corticosteroid need 
as previously reported12,19). When tumor progression occurred, 
the patients were managed at the discretion of the investigator, 
and the second-line treatment protocol was recorded. The pa-
tient’s response to treatment was categorized into four groups by 
the modified WHO criteria as follows : complete remission, par-
tial remission, stable disease, and progressive disease12,19). The 
toxic effects of treatment were graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events (version 3.0), with a score of 1 indicating mild adverse ef-
fects, 2 indicating moderate adverse effects, 3 indicating severe 
adverse effects, 4 indicating life-threatening adverse effects, and 
5 denoting death that was related to the adverse effect. The 
methylation status of the O6-methylguanine-DNA methyltrans-
ferase (MGMT) promoter was evaluated using the methylation 
specific polymerase chain reaction.
Statistical analysis
The primary endpoint was overall survival (OS), and the sec-
ondary endpoints were progression-free survival (PFS) and safe-
ty. PFS was defined as the time from diagnosis to documented 
disease progression or death from any cause, whichever oc-
curred first. OS was measured from the date of diagnosis to the 
date of death or the last follow-up examination. PFS and OS 
were estimated using the Kaplan-Meier method. Differences 
with regard to survival and disease progression were tested for 
significance using the two-sided log rank test. The Cox propor-
tional hazards model was used to adjust for stratification factors 
and other confounding variables. All these analyses were per-
formed using the SPSS statistical software package (release 
17.0.1, 2008; SPSS, Chicago, IL, USA). The toxicities of temo-
zolomide were reported separately for the radiotherapy period 
and the adjuvant chemotherapy period.
RESULTS
Patient characteristics and delivery of treatments
Between 2004 and 2007, 103 patients from four institutions 
were enrolled in this study. Their clinical characteristics at base-
line are summarized in Table 1. The median age of the patients 
was 57 years (range, 18-77 years). Sixty-seven patients (65%) 
and 62 patients (60%) showed a KPS score of over 90 at diagno-
sis and after CCRT, respectively. Fifty-seven patients (55%) un-
derwent GTR, 18 patients (18%) had STR, 6 patients (6%) expe-
rienced PR, and 22 patients (21%) had a biopsy only. Evaluation 
of the methylation of the MGMT promoter in 30 tumors re-
vealed that 14 patients (47%) had MGMT promoter methylation.
In this trial, 98 patients (95%) were given CCRT, and the re-
protocol for Korean patients with primary glioblastomas and to 




Patients over the age of 17 with a newly diagnosed and histo-
pathologically confirmed glioblastoma were enrolled from 4 in-
stitutions. Eligible patients had a Karnofsky Performance Scale 
(KPS) score ≥60 and adequate hematological, renal, and hepat-
ic functions, which were defined as an absolute neutrophil 
count ≥1500/μL, a platelet count ≥100000/μL, hemoglobin ≥10 
g/dL, serum creatinine and total serum bilirubin levels less than 
1.5 times the upper limit of the normal range, aspartate amino-
transferase and alanine aminotransferase levels less than 2.5 
times the upper limit of the normal range, and alkaline phos-
phatase levels less than 2 times the upper limit of the normal 
range. All patients were required to sign a form giving their ful-
ly informed consent to take part in the study, which was ap-
proved by the respective institutional review boards of the four 
institutions.
Treatment protocols
The patients enrolled in this study were treated with CCRT and 
adjuvant chemotherapy using temozolomide with the Stupp’s 
regimen17,18). Within 6 weeks after the histological diagnosis of 
glioblastoma, the patients were assigned to receive CCRT with 
temozolomide. According to this protocol, the radiotherapy 
component consisted of fractionated focal irradiation at a dose 
of 2 Gy per fraction given once a day, 5 days a week, for a period 
of 6 weeks, for a total dose of 60 Gy. Temozolomide was given at 
a dose of 75 mg/m2/day, 7 days per week, from the first to the 
last day of radiotherapy and for no longer than 49 days. Temo-
zolomide was administered daily 1 hour before radiotherapy or 
in the morning on days without radiotherapy.
After a 4-week break, the patients received up to six cycles of 
adjuvant temozolomide, according to the standard 5-day sched-
ule, every 28 days. The temozolomide dose was 150 mg/m2 for 
the first cycle, and it was increased to 200 mg/m2 at the begin-
ning of the second cycle if no hematological toxicity occurred. 
Prophylaxis for Pneumocystis jiroveci pneumonia was recom-
mended during CCRT or if the lymphocyte counts decreased 
below 500/mm3.
Follow-up and evaluations
The baseline evaluations included a detailed patient history, a 
physical and neurological examination, KPS score determina-
tion, hematological and serological evaluation, and brain mag-
netic resonance (MR) images with gadolinium enhancement. 
MR scans were performed before the first adjuvant treatment cy-
cle, every 2 or 3 months during the first year and every 3 months 
during the second year. The extent of resection was evaluated us-
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(27%) demonstrated complete response, 33 patients (45%) had 
partial response, 14 patients (19%) had stable disease, 6 patients 
(8%) had progressive disease as a best response. The objective 
response rate (complete and partial response) was 73%, and the 
tumor control rate (complete and partial response and stable 
disease) was 92%. At the time of analysis, 67 patients (65%) had 
died, and the median follow-up time was 17 months (range, 
1-79 months).
The Kaplan-Meier analyses were performed with the 96 pa-
tients who completed the CCRT. The median OS of these pa-
tients was 18 months [95% confidence interval (CI), 14.8-21.2] 
and the 6-, 12-, 18-, and 24-month OS were 95.7, 73.7, 48.7 and 
38.0%, respectively. The median PFS was 10.0 months (95% CI : 
8.8-11.2) and the 6-, 12-, 18-, and 24-month PFS were 75.7, 
32.7, 20.1, and 16.4%, respectively. The PFS and OS values are 
summarized in Table 3, and the Kaplan-Meier survival curves 
of the patients with newly diagnosed glioblastomas are illustrat-
ed in Fig. 1.
Prognostic factors, including the age at diagnosis, sex, tumor 
location, preoperative KPS, postoperative KPS, extent of surgical 
resection and MGMT promoter methylation were analyzed in 
maining 5 patients were given adjuvant temozolomide as an ini-
tial therapy. Among the 98 patients, 2 patients were excluded be-
cause of loss at follow-up. Finally, 54 patients (52%) completed 6 
cycles of adjuvant temozolomide, and 15 patients (15%) received 
salvage chemotherapy including nimustine (ACNU), lomustine 
(CCNU), cisplatin, avastin or irinotecan. Table 2 summarizes 
the details of the treatments administered to these patients. The 
median therapeutic radiation dose was 59.4 Gy (range, 0.8-70.0 
Gy), and the median duration of CCRT was 6.3 weeks. The pa-
tients underwent a median of 6 cycles (range, 1-15) of adjuvant 
temozolomide, and the total duration of concurrent and adju-
vant chemotherapy with temozolomide was 26.7 weeks. Twenty-
six and thirteen patients received corticosteroid therapy during 
CCRT and adjuvant chemotherapy, respectively.
 Survival and progression
Of the 73 patients with available response data, 20 patients 
Table 1. Demographic characteristics of the 103 patients at baseline
Characteristics Values
Age (years)
    Median (range)  57 (18‒77)
    ≥50  68 (66%)
    <50  35 (34%)
Sex
    Male  55 (53%)
    Female  48 (47%)
KPS (LPS) at diagnosis
      60    3 (3%)
      70    6 (6%)
      80  27 (26%)
      90  48 (47%)
    100  19 (19%)
KPS (LPS) after CCRT
    ≤60    7 (7%)
       70    9 (9%)
       80  25 (24%)
       90  43 (42%)
     100  19 (19%)
Extent of surgery
    Gross total removal  57 (55%)
    Subtotal removal  18 (18%)
    Partial removal    6 (6%)
    Biopsy only  22 (21%)
Time to diagnosis to radiotherapy (week)
    Median (range) 2.9 (1.1‒48.0)
Methylation of MGMT promoter
    Yes  14 (47%)
    No  16 (53%)
    Data not available  73
KPS (LPS) : Karnofsky Performance Scale (Lansky Play Performance Scale), 
CCRT : concurrent chemoradiotherapy, LOH : loss of heterozygosity, MGMT : O6-
methylguanine-DNA methyltransferase
Table 2. Treatment details and intensities
Variables Values
Treatment delivery
    CCRT started 98 (95%)
    CCRT completed 96 (93%)
    Adjuvant temozolomide started 91 (88%)
    Six cycles of adjuvant temozolomide competed 54 (52%)
    Salvage chemotherapy 15 (15%)
Dose of RT (Gy)
    Median 59.4
    Range 0.8‒70.0
Duration of CCRT (weeks)
    Median 6.3
    Range 0.3‒15.0
Duration of CCRT+adjuvant TMZ (weeks)
    Median 26.7
    Range 0.3‒101.3
Cycles of adjuvant TMZ
    Median 6
    Range 1‒15
Corticosteroid therapy
    During CCRT (n=98) 26 (27%)
    During adjuvant chemotherapy (n=91) 13 (14%)
Best response to CCRT and adjuvant TMZ (n=73)
    Complete remission 20 (27%)
    Partial remission 33 (45%)
    Stable disease 14 (19%)
    Progressive disease   6 (8%)
    Data not available 30
RT : radiotherapy, CCRT : concurrent chemoradiotherapy, TMZ : temozolomide
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significant (hazard ratio, 2.277; 95% CI, 1.381-3.754; p=0.001 
and hazard ratio, 1.931; 95% CI, 1.234-3.023; p=0.004, respec-
tively). The PFS and OS values of these groups are summarized 
in Table 3, and the Kaplan-Meier survival curves are illustrated 
in Fig. 2.
these patients. Among these factors, the only significant OS and 
PFS prognostic factor was the extent of surgical resection. The 
median OS and PFS of the GTR group (25.0 and 11.0 months, 
respectively) were longer than those of the STR, PR and biopsy 
groups (14.0 and 8.0 months, respectively); this difference was 
Table 3. OS and PFS of patients with newly diagnosed glioblastomas
Variables Total patients (n=96)* GTR (n=53)* STR, PR or Bx (n=43)*
Median OS (months)   18.0 (14.8-21.2)     25.0 (13.9-36.1)†   14.0 (11.0-17.0)
OS (%)
    At 6 months   95.7 (91.6-99.8)   98.1 (94.4-100.0)     92.5 (84.3-100.0)
    At 12 months   73.7 (64.6-82.7) 88.5 (79.9-97.2)   64.2 (49.2-79.3)
    At 18 months   48.7 (38.2-59.1) 58.4 (44.7-72.0)   35.5 (20.3-50.6)
    At 24 months   38.0 (27.8-48.2) 50.1 (36.2-64.0) 21.8 (8.6-35.1)
Median PFS (months) 10.0 (8.8-11.2)  11.0 (9.4-12.6)†   8.0 (5.7-10.3)
PFS (%)
    At 6 months   75.7 (67.0-84.3) 88.7 (80.2-97.2)   59.0 (44.0-74.0)
    At 12 months   32.7 (23.2-42.3) 48.7 (35.2-62.3)   32.0 (17.7-46.3)
    At 18 months   20.1 (11.8-28.4) 28.7 (16.2-41.1)   9.2 (0.0-18.4)
    At 24 months 16.4 (8.6-24.1) 24.3 (12.3-36.2)   6.2 (0.0-14.0)
*Range, 95% confidence interval, †The OS and PFS of the patients with GTR was statistically greater than that of the patients with STR, PR or Bx (hazard ratio, 2.277; 
95% CI, 1.381-3.754; p=0.001 and hazard ratio, 1.931; 95% CI, 1.234-3.023; p=0.004, respectively). OS : overall survival, PFS : progression-free survival, GTR : 
gross total removal, NTR : near total removal, STR : subtotal removal, PR : partial removal, Bx : biopsy
Fig. 1. Kaplan-Meier estimates of (A) overall survival (OS) and (B) progression-free survival (PFS) in 96 patients suffering from newly diagnosed glio-
blastoma who were treated with temozolomide during and after radiotherapy.
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present, CCRT followed by adjuvant chemotherapy with temo-
zolomide is widely accepted as a standard protocol for patients 
newly diagnosed with a glioblastoma. Since the Stupp report, 
most Korean institutions use this concurrent protocol with te-
mozolomide for primary glioblastoma treatments. Some single 
center studies reported the outcome of CCRT followed by adju-
vant chemotherapy with temozolomide for Korean patients us-
ing Stupp’s regimen3,7,8,10,14).
However, there have been no reported multicenter trial data 
from Korea. The objective of this study was to report the cur-
rent results of a prospective multicenter clinical trial investigat-
ing the use of CCRT with temozolomide in Korea and to deter-
mine a standard treatment protocol for Korean patients with a 
primary glioblastoma. A total of 103 patients from 4 institutes 
were enrolled in this study, and 93 and 54% of these patients 
completed the CCRT and adjuvant chemotherapy with temo-
zolomide, respectively. These completion rates were compara-
ble to the results of a previous well-designed globalized trial18).
Notably, the median PFS and OS of patients with glioblasto-
ma treated with CCRT were 10.0 and 18.0 months respectively. 
This result seems to be slightly more favorable than Stupp’s re-
sults and similar to that of a single center study in Korea3,7,18). It 
is possible that the effect of temozolomide may be more favor-
able in Korean patients than in other patients. However, there 
has not been any evidence in support of this assumption exists, 
and more sophisticated studies should be designed to test this 
hypothesis.
The favorable outcome of the CCRT with TMZ in Korean pa-
tients may be due to the higher rate of patients with GTR in Ko-
rea than those in the Stupp’s study. While 40% of the patients in 
Stupp’s study underwent GTR, 55% of the patients in this study 
underwent GTR18). In effect, the only significant prognostic fac-
tor of OS and PFS was the extent of surgical resection in this 
study. Recent studies also reported that the extent of surgical re-
section was a significant prognostic factor for patients with a 
primary glioblastoma3,8,11,16). These data suggest that the more fa-
vorable survival rate in our study as compared with Stupp’s study 
may be due to the higher GTR rate.
Unfortunately, this study revealed that other prognostic fac-
tors, including age, KPS score, and MGMT promoter methyla-
tion status, were not significant prognostic factors. This is prob-
ably because MGMT promoter methylation was investigated in 
such a small number of patients. To reach a definitive conclu-
sion, future studies should include additional data regarding bi-
ological factors, such as methylation of the MGMT promoter, 
for all or most of the studied patients9).
The treatment protocol used in this study was already recog-
nized as the standard protocol for newly diagnosed glioblasto-
ma, and this issue is the limitation of this study. Moreover, this 
study lacks the control group and is not a randomized compar-
ative study. However, this study was the first prospective multi-
institutional study for the glioblastoma treatment in Korean pa-
tients. Therefore, the further randomized controlled study is 
Toxicity
The adverse events were analyzed separately by the period of 
CCRT and adjuvant therapy with temozolomide. During the 
CCRT with temozolomide treatment, 8 (8.1%) patients pre-
sented with grade 3 or 4 hematological toxicities, including 1 
patient with leukopenia, 2 with neutropenia, 3 with lymphope-
nia, and 5 with anemia. Non-hematological toxic effects during 
the CCRT period tended to be grade 1 or 2. During the adju-
vant therapy period, 16 (17.6%) patients presented with grade 3 
or 4 hematological toxicities, including 6 patients leukopenia, 3 
with neutropenia, 5 with lymphopenia, 7 with thrombocytope-
nia, and 3 with anemia. Non-hematological toxicity during the 
adjuvant therapy period was not available. All the patients that 
experienced toxicities from the chemotherapeutic agent re-
ceived the delayed chemotherapy and tolerated the treatment 
well during therapy. No opportunistic infections were noted. 
The distribution of the CCRT and adjuvant therapy with temo-
zolomide-related toxicities is shown in Table 4.
DISCUSSION
Only a few years ago, most patients who were diagnosed with 
primary glioblastoma died despite combination therapy including 
microsurgery, radiotherapy, and chemotherapy18). However, post-
operative adjuvant treatments have evolved into a new era since 
the introduction of the chemotherapeutic drug temozolomide.
Temozolomide, which is a second-generation oral alkylating 
agent, performs antitumor activity by methylating the guanine 
residues of tumor cell DNA, thus creating a mismatch that an 
enzyme repair system cannot fix2,8,15). Temozolomide has dem-
onstrated antitumor activity in the treatment of malignant glio-
mas and has been approved for the treatment of recurrent ma-
lignant glioma and newly diagnosed glioblastoma1,5,6,17,20). A 
randomized prospective study reported in 2005 showed that 
CCRT with temozolomide was more effective than radiothera-
py alone in patients newly diagnosed and histopathologically 
confirmed to have a glioblastoma18). The patients in this study 
had a median OS of 14.6 months for CCRT with temozolomide 
and 12.1 months for radiotherapy alone. The 2-year survival 
rate was also higher for patients treated using CCRT with te-
mozolomide (26.5%) than with radiotherapy alone (10.4%). At 
Table 4. Grade 3 or 4 hematologic toxic effects in patients treated with 
temozolomide
Toxicity CCRT with TMZ (n=98)
Adj with TMZ 
(n=91)
Leukopenia 1 (1%) 6 (7%)
Neutropenia 2 (2%) 3 (3%)
Lymphopenia 3 (3%) 5 (5%)
Thrombocytopenia 0 (0%) 7 (8%)
Anemia 5 (5%) 3 (3%)
CCRT : concurrent chemoradiotherapy, TMZ : temozolomide, Adj : adjuvant che-
motherapy
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mide during and after radiation therapy for WHO grade III gliomas : pre-
liminary report of a prospective multicenter study. J Neurooncol 103 : 
503-512, 2011
9. Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, et al. : MGMT 
Gene Promoter Methylation as a Potent Prognostic Factor in Glioblas-
toma Treated with Temozolomide-Based Chemoradiotherapy : A Sin-
gle-Institution Study.  Int J Radiat Oncol Biol Phys : 2012. Inpress
10. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, et al. : Phase II trial 
of low-dose continuous (metronomic) treatment of temozolomide for 
recurrent glioblastoma. Neuro Oncol 12 : 289-296, 2010
11. Lakomý R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarová E, et al. : 
[Multimodal treatment of glioblastoma multiforme : results of 86 con-
secutive patients diagnosed in period 2003-2009]. Klin Onkol 24 : 112-
120, 2011
12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response 
criteria for phase II studies of supratentorial malignant glioma. J Clin 
Oncol 8 : 1277-1280, 1990
13. Omar AI, Mason WP : Temozolomide : The evidence for its therapeutic 
efficacy in malignant astrocytomas. Core Evid 4 : 93-111, 2010
14. Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, et al. : Usefulness of 
MS-MLPA for detection of MGMT promoter methylation in the evalu-
ation of pseudoprogression in glioblastoma patients. Neuro Oncol 13 : 
195-202, 2011
15. Siker ML, Chakravarti A, Mehta MP : Should concomitant and adjuvant 
treatment with temozolomide be used as standard therapy in patients 
with anaplastic glioma? Crit Rev Oncol Hematol 60 : 99-111, 2006
16. Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, et al. : Long-term 
outcomes in children with glioblastoma. J Neurosurg Pediatr 6 : 145-
149, 2010
17. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder 
P, et al. : Promising survival for patients with newly diagnosed glioblas-
toma multiforme treated with concomitant radiation plus temozolo-
mide followed by adjuvant temozolomide. J Clin Oncol 20 : 1375-1382, 
2002
18. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn 
MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide 
for glioblastoma. N Engl J Med 352 : 987-996, 2005
19. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, 
Galanis E, et al. : Updated response assessment criteria for high-grade 
gliomas : response assessment in neuro-oncology working group. J Clin 
Oncol 28 : 1963-1972, 2010
20. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. : 
A phase II study of temozolomide vs. procarbazine in patients with 
glioblastoma multiforme at first relapse. Br J Cancer 83 : 588-593, 2000
also needed for improving the survival of Korean glioblastoma 
patients. The results of this study can become control data for 
this further trial.
CONCLUSION
The CCRT and adjuvant chemotherapy with temozolomide 
may prolong the survival of Korean patients with a glioblasto-
ma and may be tolerable in terms of toxicity. The significance of 
this study is that our study results may help in determining a 
proper chemoradiotherapy regimen for newly diagnosed glio-
blastomas in Korea by proving the effectiveness and safety of 
Stupp’s regimen in Korean patients. The results of this study are 
also expected to serve as control data for further randomized 
comparative trials for patients with a glioblastoma in Korea.
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